No correlation between alpha-1-antitrypsin phenotype and lung, prostate, or breast cancer in Jordan

Our results suggest that alpha(1)ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.

lung and prostate cancer patients have shown a significant elevation in alpha1-AT serum levels compared with healthy controls; breast cancer patients did not show a significant change in these levels

variants of AAT and neutrophil elastase genotypes with predicted intermediate or high activity could represent a risk factor for aggressive form of lung cancer

Increased serum alpha 1-antitrypsin is associated with non-small cell lung cancer.

Increased Alpha-1-antitrypsin level is associated with chemoresistance in non-small cell lung cancer.

high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients.

This study suggested that high a1-antitrypsin (AAT)expression might be a negative prognostic marker for lung adenocarcinoma. AAT promoted lung adenocarcinoma metastasis, whose functional target may be fibronectin . Our findings provide new insight into the mechanisms of lung adenocarcinoma metastasis

Proteomic and genomic biomarkers for Non-Small Cell lung cancer: Peroxiredoxin, Haptoglobin, and Alpha-1 antitrypsin.